What is the standard therapy for bulky stage IB cervical cancer?

International Journal of Gynecological Cancer

Volumn 19, Issue 3, 2009, Pages 480-

  Monk, Bradley J ^a   Koh, Wui Jin ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN DERIVATIVE;

BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; HUMAN; LETTER; PRIORITY JOURNAL; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

COMBINED MODALITY THERAPY; FEMALE; HUMANS; NEOPLASM STAGING; UTERINE CERVICAL NEOPLASMS;

EID: 68149137755     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/GC.0b013e3181a131c5     Document Type: Letter

References (4)

1. Petsuksiri J., Chansilpa Y., Therasakvichya S., et al. Treatment options in bulky stage IB cervical carcinoma. Int J Gynecol Cancer. 2008;18:1153-1162.
2. Monk BJ, Tewari KS, Koh WJ. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol. 2007;25:2952-2965.
3. Stehman FB, Ali S., Keys HM, et al. Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. Am J Obstet Gynecol. 2007;197:503.e1-503.e6.
4. Yessaian A., Magistris A., Burger RA, et al. Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy. Gynecol Oncol. 2004;94:61-66. Copyright © 2009 by IGCS and ESGO.